- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Web-Based Tool Designed to Improve Quality of Care in Thyroid Cancer
The Thyroid Cancer Clinical Registry is expected to improve quality of patient care as patient data would be readily available to all physicians involved in the patients care; however former Commission on Cancer chair Frederick L Greene, MD, wonders whether physicians would take the time to enter the clinical data into the system as required.
A recently launched web-based disease-management tool for thyroid cancer is designed to improve quality of care as well as provide richer data for research than is available from current cancer databases.
Funded by philanthropy, the Thyroid Cancer Care Collaborative(TCCC) is maintained by the patient and includes clinical data across sites of care along with clinical decision-support and education components. It is intended for use by all physicians involved in the care of patients with thyroid cancer, including endocrinologists, oncologists, nuclear-medicine specialists, radiologists, surgeons, and primary-care physicians.
"It's basically their medical record on a cloud," R Michael Tuttle, MD, of Memorial Sloan Kettering Cancer Center and Cornell University, New York, told Medscape Medical News.
Link to the complete article on Medscape:
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
